Authors

Latest:

Dr Munshi on the Background of the CARTITUDE-1 Trial in Multiple Myeloma

Nikhil C. Munshi, MD, discusses the background of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and highlights the specific patient population enrolled in the study.

Nikhil Khushalani, MD

Latest:

Dr Khushalani on Fixed-Dose Treatment Regimens in Advanced Melanoma

Nikhil Khushalani, MD, discusses the benefits and limitations of fixed-dose treatment regimens in patients with unresectable or metastatic melanoma.

Nikolaos Pyrsopoulos, MD, PhD Rutgers New Jersey Medical School

Nilanjan Ghosh, MD, PhD

Latest:

Safety Considerations for Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

A review of studies on safety management with CAR T-cell therapy, focusing on CRS/ICANS in the relapsed/refractory setting, key takeaways from Cohorts 4 and 6, and the impact of ZUMA-24 preliminary analysis on second-line safety strategies.

Nilanjan Ghosh, MD, PhD, Levin Cancer Institute

Nilanjan Ghosh, MD, PhD, Levine Cancer Institute/Atrium Health

Nils D. Arvold, MD

Latest:

The Role of Radiation in the Management of Brain Metastases

In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.

Nimmi S. Kapoor, MD

Latest:

Dr. Nimmi Kapoor on Multigene Panel Testing for Hereditary Breast Cancer

Nimmi Kapoor, MD, Breast and Thyroid Surgical Oncologist at Breastlink, discusses the benefits and safety of multigene panel testing in patients at risk for hereditary breast cancer.

Nina Shah, MD

Latest:

Unmet Needs in the Management of Multiple Myeloma

Sagar Lonial, MD, provides insight on mechanisms of resistance to CAR T-cell therapies, and the panel shares unmet needs and future directions for the treatment of multiple myeloma.

Nina Shah, MD, UCSF

Nir Peled, MD PhD

Latest:

Dr. Peled on the Rationale of Evaluating Lenvatinib/Pembrolizumab with Chemotherapy in NSCLC

Nir Peled, MD, PhD, FCCP, discusses the rationale of evaluating the combination of lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

Niraj Mehta, MD

Latest:

Dr. Mehta Discusses the Reliability of Automated Segmentation for Lung Volumes in Multiple Cancers

Niraj Mehta, MD, Radiation Oncologist, 21st Century Oncology, discusses the reliability of automated segmentation for lung volumes in breast, lung, and esophageal cancers.

Nirali N. Shah, MD, MHSc

Latest:

Dr. Shah on CAR T-Cell Therapy in Pediatric ALL

Nirali N. Shah, MD, MHSc, discusses the use of CAR T-cell therapy in pediatric patients with acute lymphocytic leukemia.

Nirav N. Shah, MD

Latest:

Dr Shah on Unmet Needs in the Treatment of Older Patients with DLBCL

Nirav N. Shah, MD, discusses the rationale for launching a phase 2 trial of split-dose R-CHOP in older patients with diffuse large B-cell lymphoma, touching on the unmet needs seen in the treatment of this population.

Nirmish Singla, MD

Latest:

Oncology Fellow Stresses Integrity in the Lab and Clinic

Research forms the backbone of medical knowledge, and research integrity is a crucial responsibility of any scientist.

Nisha Bansal, MD

Latest:

Dr. Bansal on Chemotherapeutic Approaches for Patients With Ovarian Cancer

Nisha Bansal, MD, gynecologic oncologist, University of California, Los Angeles, discusses frontline chemotherapeutic approaches for patients with ovarian cancer.

Nitika Thawani, MD

Latest:

Dr. Thawani on AEs With Radiation Versus COVID-19 Symptoms in Lung Cancer

Nitika Thawani, MD, discusses identifying the difference between adverse events that are associated with radiation versus COVID-19 symptoms in lung cancer.

Nitin Jain, MD

Latest:

The Impact of Emerging Resistance Patterns on Treatment Sequencing in R/R CLL

Panelists discuss how emerging resistance patterns in chronic lymphocytic leukemia influence their approach to treatment sequencing, considering the mechanisms of resistance to different drug classes and how this knowledge informs the selection and order of therapies to maximize long-term disease control and patient outcomes.

Nitya A. Narayan, MD

Latest:

Medical Ethics in Pediatric Oncology

Everyone, at every level, is checking, rechecking, thinking, researching, asking questions, discussing, analyzing, and trying to help patients.

Nitya Narayan, MD

Latest:

Work-Life Balance of a Hem/Onc Fellow

I am a member of the cohort of 30-something single Indian women who were not lucky enough to snag the right guy during med school, and perhaps am not genetically engineered to be good at dating and studying simultaneously.